NCT06769633 - Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 2, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

Givinostat Hydrochloride

Cohort 1 - from 4 to 6 years old

DRUG

Givinostat Hydrochloride - Cohort 2

Cohort 2 - from 2 to 4 years old

Trial Locations (9)

RECRUITING

Queen Fabiola Children's University Hospital HUDERF, Brussels

RECRUITING

Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca' Granda - NeuroMuscolar Omnicenter, Milan

RECRUITING

Ospedale Pediatrico Bambino Gesù, Roma

RECRUITING

Policlinico Universitario Agostino Gemelli - Università Cattolica del Sacro Cuore, Roma

RECRUITING

Leids Universitair Medisch Centrum (LUMC), Leiden

NOT_YET_RECRUITING

Leeds Teaching Hospital NHS Trust, Leeds

NOT_YET_RECRUITING

Great Ormond Street Hospital - GOSH, London

RECRUITING

Newcastle upon Tyne Hospitals NHS Foundation Trust - Newcastle University, Newcastle upon Tyne

RECRUITING

Oxford University Hospitals NHS Foundation Trust, Oxford